Novel oxazolidinone deriviatives

ABSTRACT

The present invention relates to oxazolidinone derivatives of formula (I) wherein Y, R 3  and R 4  are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

The present invention relates to novel oxazolidinone derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as orexin receptor antagonists.

Orexins (orexin A or OX-A and orexin B or OX-B) are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to the G-protein-coupled receptors (OX₁ and OX₂ receptors). The orexin-1 receptor (OX₁) is selective for OX-A, and the orexin-2 receptor (OX₂) is capable to bind OX-A as well as OX-B. Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R. M. et al., Cell, 1999, 98, 437-451). Furthermore, in vitro and in vivo evidence for a critical role of orexin signaling in the ventral tegmental area in neural plasticity relevant to addiction has been published (S. L. Borgland et al. Neuron, 2006, 49, 589-601).

Thus, orexin receptors may have numerous implications in pathologies as known from the literature, such as dysthymic, mood, psychotic and anxiety disorders; diabetes and appetite, taste, eating, or drinking disorders; hypothalamic diseases; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; insomnias related to psychiatric disorders; sleep apnea; narcolepsy; idiopathic insomnias; parasomnias; benign prostatic hypertrophy; all dementias and cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders; and other diseases related to general orexin system dysfunctions. The compound (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenyl-acetamide (WO2005/118548) is currently in clinical development for primary insomnia. In the rat, the compound has been shown for example to decrease alertness, characterized by decreases in both active wake and locomotion; and to dose-dependently increase the time spent in both REM and NREM sleep (F. Jenck et al., Nature Medicine 2007, 13, 150-155). The compound has also been shown to enhance memory function in a rat model (WO2007/105177) and is also active in a rat model of post-traumatic stress disorder (WO2009/047723).

The present invention provides novel oxazolidinone derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of diseases related to the orexin system, especially comprising all types of sleep disorders, of stress-related syndromes, of addictions (especially psychoactive substance use, abuse, seeking and reinstatement), of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.

1) A first aspect of the invention consists of compounds of the formula (I)

wherein Y represents CH₂, CHR¹, or CR¹R²; wherein

-   -   R¹ and R² independently represent (C₁₋₄)alkyl;         R³ represents Ar¹ or Ar³—Z—Ar²—* wherein the asterisk indicates         the bond that is attached to the rest of the molecule; wherein     -   Ar¹ represents aryl or heteroaryl, wherein the aryl or         heteroaryl is independently unsubstituted, or mono-, di-, or         tri-substituted, wherein the substituents are independently         selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy,         halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy,         (C₁₋₃)fluoroalkyl-thio-, and (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy;     -   Ar² represents phenyl or 5- to 6-membered heteroaryl;     -   Z represents a bond, O, or —CH₂—O—* wherein the asterisk         indicates the bond that is attached to Ar²;     -   Ar³ represents phenyl or 5- to 6-membered heteroaryl wherein the         phenyl or 5- to 6-membered heteroaryl is independently         unsubstituted, or mono-, di-, or tri-substituted, wherein the         substituents are independently selected from the group         consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably substituents         are selected from (C₁₋₄)alkyl, (C₁₋₄)alkoxy, and         (C₁₋₃)fluoroalkyl); and         R⁴ represents aryl or heteroaryl, wherein the aryl or heteroaryl         is independently mono-, di-, or tri-substituted, wherein the         substituents are independently selected from the group         consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, hydroxy-(C₁₋₄)alkoxy, and         (C₁₋₄)alkoxy-(C₁₋₄)alkoxy; wherein, in the specific case wherein         said aryl or heteroaryl is a bicyclic ring, the aryl or         heteroaryl may also be unsubstituted;         with the exception of the following compounds:

-   2-(2-bromophenyl)-3-[(4-methoxyphenyl)methyl]-4-oxazolidinone (CAS     199939-14-5);

-   2-(2-bromophenyl)-3-{[4-(trifluoromethyl)phenyl]methyl}-4-oxazolidinone     (CAS 199939-13-4);

-   2-(2-bromophenyl)-3-(phenylmethyl)-4-oxazolidinone (CAS     199939-09-8); and

-   2-(4-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]-5-methyl-4-oxazolidinone     (CAS 84711-84-2).

The latter compounds are known from L. Giraud, E. Lacote, P. Renaud; “Preparation of 2-arylbenzaldehyde derivatives via free-radical ipso-substitution of an amidomethyl group” Helv. Chim. Acta (1997), 80(7), 2148-2156; and H. Aoyama, M. Sakamoto, K. Kuwabara, K. Yoshida, Y. Omote; “Photochemical reactions of .alpha.-oxo amides. Norrish type II reactions via zwitterionic intermediates” J. Am. Chem. Soc. (1983), 105(7), 1958-64.

In this patent application, a bond interrupted by a wavy line shows the point of attachment of the radical drawn. For example, the radical drawn below

is the 7-methoxy-quinolin-8-yl group.

The term “halogen” means fluorine, chlorine, or bromine, preferably fluorine or chlorine.

The term “alkyl”, used alone or in combination, refers to a saturated straight or branched chain alkyl group containing one to four carbon atoms. The term “(C_(x-y))alkyl” (x and y each being an integer), refers to an alkyl group as defined before containing x to y carbon atoms. For example a (C₁₋₄)alkyl group contains from one to four carbon atoms. Examples of (C₁₋₄)alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl. Preferred are methyl and ethyl. Most preferred is methyl. For the substituents R¹ and R² preferred is methyl. For the substituent R¹⁵ representing a (C₁₋₄)alkyl group, preferred are ethyl, n-propyl and especially isopropyl.

The term “cycloalkyl”, used alone or in combination, refers to a saturated cyclic alkyl group containing three to six carbon atoms. The term “(C_(x-y))cycloalkyl” (x and y each being an integer), refers to a cycloalkyl group as defined before containing x to y carbon atoms. For example a (C₃₋₆)cycloalkyl group contains from three to six carbon atoms. Examples of (C₃₋₆)alkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Preferred is cyclopropyl.

The term “alkoxy”, used alone or in combination, refers to an alkyl-O— group wherein the alkyl group is as defined before. The term “(C_(x-y))alkoxy” (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example a (C₁₋₄)alkoxy group means a group of the formula (C₁₋₄)alkyl-O— in which the term “(C₁₋₄)alkyl” has the previously given significance. Examples of (C₁₋₄)alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy. Preferred are ethoxy and especially methoxy. For substituents of R⁴ preferred examples are ethoxy and methoxy. For substituents of Ar¹ representing a phenyl group preferred examples are methoxy, ethoxy and especially isopropoxy.

The term “fluoroalkyl” refers to an alkyl group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term “(C_(x-y))fluoroalkyl” (x and y each being an integer) refers to a fluoroalkyl group as defined before containing x to y carbon atoms. For example a (C₁₋₃)fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkyl groups include trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl. Preferred are (C₁)fluoroalkyl groups such as trifluoromethyl. For the substituent R¹⁵ preferred examples are trifluoromethyl, difluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl (notably trifluoromethyl, difluoromethyl, and 2,2,2-trifluoroethyl).

The term “fluoroalkoxy” refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term “(C_(x-y))fluoroalkoxy” (x and y each being an integer) refers to a fluoroalkoxy group as defined before containing x to y carbon atoms. For example a (C₁₋₃)fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy. Preferred are (C₁)fluoroalkoxy groups such as trifluoromethoxy and difluoromethoxy.

The term “aryl”, alone or in combination, means a phenyl or a naphthyl group. In addition, the term aryl also comprises phenyl rings fused to a 5- or 6-membered saturated or partially unsaturated non-aromatic ring optionally containing 1 to 2 oxygen atoms. Examples of aryl groups are phenyl, naphthyl, indanyl, tetrahydronaphthyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, chromanyl, and chromenyl. In a sub-embodiment, examples are phenyl, naphthyl, indanyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzofuranyl, and 2,3-dihydro-benzo[1,4]dioxinyl. In another sub-embodiment examples are phenyl or naphthyl, notably phenyl. The aryl group may be unsubstituted or substituted as explicitly defined. The sub-group wherein aryl groups are phenyl rings fused to a 5- or 6-membered saturated or partially unsaturated non-aromatic ring optionally containing 1 or 2 oxygen atoms is preferably unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from the group consisting of methyl, methoxy, and halogen.

For the substituent Ar¹ particular examples of aryl groups are phenyl, 2-naphthyl, 6-methoxy-naphthalen-2-yl, 1-naphthyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-fluorophenyl, 3-fluorophenyl, 2-fluorophenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 2,6-dimethylphenyl, 3-fluoro-4-methylphenyl, 3-chloro-4-methylphenyl, 4-fluoro-3-methylphenyl, 3,4-difluorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-6-fluorophenyl, 2-chloro-4-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-difluoro-phenyl, 3,5-difluoro-phenyl, 2,5-difluoro-phenyl, 2,6-difluoro-phenyl, 3,4,5-trifluoro-phenyl, 2-chloro-3,6-difluorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2-methoxyphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2,4,6-trimethylphenyl, 4-ethoxyphenyl, 2-ethoxyphenyl, 4-(n-propoxy)phenyl, 4-isopropoxyphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 4-tert.butyl-phenyl, 2,6-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2-difluoromethoxy-phenyl, 4-difluoromethoxyphenyl, 4-trifluoromethyl-sulfanyl-phenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5-trifluoromethylphenyl, 3-fluoro-4-trifluoromethylphenyl, 4-fluoro-3-trifluoromethylphenyl, 2-fluoro-4-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-chloro-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-fluoro-3-chloro-5-trifluoromethylphenyl, 3-fluoro-4-trifluoromethoxyphenyl, 3-chloro-4-trifluoromethoxyphenyl, 4-(2,2,2-trifluoroethoxy)phenyl, 4-tert.-butoxyphenyl, 4-(cyclopropylmethoxy)-phenyl, benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, and 2,3-dihydro-benzo[1,4]dioxin-6-yl. In a sub-embodiment examples are 2-naphthyl, 4-chlorophenyl, 2-chlorophenyl, 4-fluorophenyl, 2-fluorophenyl, 3-methylphenyl, 2-methylphenyl, 2,6-dimethylphenyl, 3-chloro-4-methylphenyl, 4-fluoro-3-methylphenyl, 3,4-difluorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2-chloro-3,6-difluorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2,4,6-trimethylphenyl, 4-ethoxyphenyl, 4-(n-propoxy)phenyl, 4-isopropoxyphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-difluoromethoxyphenyl, 4-trifluoromethyl-sulfanyl-phenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5-trifluoromethylphenyl, 3-fluoro-4-trifluoromethylphenyl, 4-fluoro-3-trifluoromethyl phenyl, 2-fluoro-4-trifluoromethyl phenyl, 2-fluoro-5-trifluoromethylphenyl, 2-chloro-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethyl phenyl, 2-fluoro-3-chloro-5-trifluoromethylphenyl, 3-fluoro-4-trifluoromethoxyphenyl, 3-chloro-4-trifluoromethoxyphenyl, 4-(cyclopropylmethoxy)-phenyl, and benzo[1,3]dioxol-5-yl.

For the substituent R⁴ particular examples of aryl groups are 2-methoxy-naphthalen-1-yl, 2,6-difluorophenyl, 2-methoxyphenyl, 2-ethoxyphenyl, 2-fluoro-6-methoxyphenyl, 2-chloro-6-methoxyphenyl, 2-methoxy-6-methylphenyl, 2-methoxy-5-methylphenyl, 2,6-dimethylphenyl, 2,6-dimethoxyphenyl, 2,5-dimethoxyphenyl, 3-chloro-2,6-dimethoxyphenyl, 2-chloro-4,6-dimethoxyphenyl, 2-fluoro-4,6-dimethoxyphenyl, 4-fluoro-2,6-dimethoxyphenyl, 2-ethoxy-6-methoxyphenyl, 2,6-diethoxyphenyl, 2-isopropoxy-6-methoxyphenyl, 3-fluoro-2,6-dimethoxyphenyl, 2,6-dimethoxy-3-methylphenyl, 2,6-dimethoxy-4-methylphenyl, 2-(2-hydroxyethoxy)-6-methoxyphenyl, 2-(2-hydroxypropoxy)-6-methoxyphenyl, 2-(3-hydroxypropoxy)-6-methoxyphenyl, 2-(2,3-dihydroxypropoxy)-6-methoxyphenyl, 2-(2-methoxyethoxy)-6-methoxyphenyl, 2,3,6-trimethoxyphenyl, 2,4,6-trimethoxyphenyl, 2-trifluoromethylphenyl, 2-methoxy-6-trifluoromethylphenyl, 6-methoxy-indan-5-yl, benzo[1,3]dioxol-4-yl, 5-methoxy-benzo[1,3]dioxol-4-yl, 5-bromo-benzo[1,3]dioxol-4-yl, 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl, 2,3-dihydro-benzo[1,4]dioxin-5-yl, and 6-methoxy-2,3-dihydro-benzo[1,4]dioxin-5-yl. In a sub-embodiment, examples are 2-ethoxyphenyl, 2-fluoro-6-methoxyphenyl, 2-chloro-6-methoxyphenyl, 2-methoxy-6-methylphenyl, 2,6-dimethylphenyl, 2,6-dimethoxyphenyl, 2-ethoxy-6-methoxyphenyl, 4-fluoro-2,6-dimethoxyphenyl, 2,6-dimethoxy-4-methylphenyl, 2-(2-hydroxyethoxy)-6-methoxyphenyl, 2-methoxy-6-trifluoromethylphenyl, 5-methoxy-benzo[1,3]dioxol-4-yl, and 6-methoxy-2,3-dihydro-benzo[1,4]dioxin-5-yl. In another sub-embodiment, examples are 2-ethoxyphenyl, 2-fluoro-6-methoxyphenyl, 2-chloro-6-methoxyphenyl, 2-methoxy-6-methylphenyl, 2,6-dimethylphenyl, 2,6-dimethoxyphenyl, 2-ethoxy-6-methoxyphenyl, and 2-methoxy-6-trifluoromethylphenyl.

For the substituent Ar¹ examples of the particular sub-group of “phenyl rings fused to a 5- or 6-membered saturated or partially unsaturated non-aromatic ring optionally containing 1 to 2 oxygen atoms” are 2,2-difluoro-benzo[1,3]dioxol-5-yl, benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, and 2,3-dihydro-benzo[1,4]dioxin-6-yl (notably benzo[1,3]dioxol-5-yl).

For the substituent R⁴ examples of the particular sub-group of “phenyl rings fused to a 5- or 6-membered saturated or partially unsaturated non-aromatic ring optionally containing 1 to 2 oxygen atoms” are 6-methoxy-indan-5-yl, benzo[1,3]dioxol-4-yl, 5-methoxy-benzo[1,3]dioxol-4-yl, 5-bromo-benzo[1,3]dioxol-4-yl, 2,2-dimethyl-2,3-dihydrobenzofuran-7-yl, 2,3-dihydro-benzo[1,4]dioxin-5-yl, and 6-methoxy-2,3-dihydro-benzo[1,4]dioxin-5-yl (notably 5-methoxy-benzo[1,3]dioxol-4-yl, and 6-methoxy-2,3-dihydro-benzo[1,4]dioxin-5-yl).

For the substituent R⁴ examples of the particular sub-group of “bicyclic aryl” are naphthyl, indanyl, tetrahydronaphthyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, chromanyl, and chromenyl (notably naphthyl, benzo[1,3]dioxolyl, and 2,3-dihydro-benzo[1,4]dioxinyl) which are unsubstituted or substituted as explicitly defined. Particular examples are 2-methoxy-naphthalen-1-yl, 5-methoxy-benzo[1,3]dioxol-4-yl, and 6-methoxy-2,3-dihydro-benzo[1,4]dioxin-5-yl.

The term “heteroaryl”, alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing 1 to a maximum of 3 heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of such heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 4H-furo[3,2-b]pyrrolyl, pyrrolo[2,1-b]thiazolyl and imidazo[2,1-b]thiazolyl. In case the heteroaryl group is a 5- to 6-membered heteroaryl as used for the generic groups Ar² and Ar³, particular examples are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, and pyrazinyl; notably pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyridazinyl, and pyrazinyl. The heteroaryl group may be unsubstituted or substituted as explicitly defined.

For the substituent Ar¹ particular examples of heteroaryl groups are thiophenyl, pyrrolyl, pyridazinyl, pyridinyl, benzo[b]thiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, benzotriazolyl, quinoxalinyl, and quinolinyl, which are unsubstituted or substituted as explicitly defined; notably thiophen-2-yl, 1-methyl-pyrrol-2-yl, 6-ethoxy-pyridazin-3-yl, pyridin-2-yl, pyridin-4-yl, 2-ethoxy-pyridin-5-yl, 5-ethoxy-pyridin-2-yl, benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, benzofuran-2-yl, 1H-benzimidazol-2-yl, 1-methyl-1H-benzimidazol-2-yl, benzoxazol-2-yl, benzothiazol-2-yl, 1-methyl-1H-indol-6-yl, 1H-indol-2-yl, 1-methyl-1H-indol-2-yl, 1H-indol-3-yl, 1-methyl-1H-benzotriazol-5-yl, quinoxalin-2-yl, quinoxalin-6-yl, quinolin-2-yl, quinolin-6-yl, and quinolin-7-yl (especially benzimidazol-2-yl, benzoxazol-2-yl, and benzothiazol-2-yl).

For the substituent R⁴ particular examples of heteroaryl groups are pyridinyl, benzo[d]isoxazolyl, benzoxazolyl, and quinolinyl which are unsubstituted or substituted as explicitly defined; notably 2,4-dimethoxypyridin-3-yl, 3,5-dimethoxypyridin-4-yl, 6-methoxy-3-methyl-benzo[d]isoxazol-7-yl, 6-methoxy-2-methyl-benzoxazol-7-yl, and 7-methoxy-quinolin-8-yl.

For the substituent R⁴ examples of the particular sub-group of “bicyclic heteroaryl” are benzo[d]isoxazolyl, benzoxazolyl, and quinolinyl which are unsubstituted or substituted as explicitly defined. Particular examples are 6-methoxy-3-methyl-benzo[d]isoxazol-7-yl, 6-methoxy-2-methyl-benzoxazol-7-yl, and 7-methoxy-quinolin-8-yl.

For the substituent Ar³ examples of the particular sub-group of “5- to 6-membered heteroaryl” are pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl which are unsubstituted or substituted as explicitly defined; notably pyrrol-1-yl, pyrazol-1-yl, thiazol-2-yl, pyridin-2-yl, pyridin-3-yl, 3-methyl-pyridin-2-yl, 4-methyl-pyridin-2-yl, 5-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl, 5-methoxy-pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-trifluoromethyl-pyridin-2-yl, pyrimidin-2-yl, pyrimidin-5-yl, 6-methyl-pyridazin-3-yl, and pyrazin-2-yl. Preferred (for the substituent Ar³, and mutatis mutandis also for the substituent R¹⁵) are thiazolyl, pyridyl and pyrazinyl which are unsubstituted or substituted as explicitly defined; notably thiazol-2-yl, pyridin-2-yl, pyridin-3-yl, 4-methyl-pyridin-2-yl, and pyrazin-2-yl; especially thiazol-2-yl, and pyridin-2-yl.

For the substituent Ar² the phenyl or 5- to 6-membered heteroaryl are preferably substituted by Z and the rest of the molecule in a para (such as phenyl-1,4-diyl) arrangement (for phenyl or 6-membered heteroaryl) or in a 1,3-arrangement (for 5-membered heteroaryl). A particular example of Ar² representing a 5- to 6-membered heteroaryl group is pyridyl, notably pyridin-2,5-diyl (wherein Z may be attached in either position 2 or 5).

The term “fluoroalkyl-thio” refers to an alkyl group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine, said group being attached to the rest of the molecule via a sulfur atom. The term “(C_(x-y))fluoroalkyl-thio” (x and y each being an integer) refers to a fluoroalkyl-thio group as defined before containing x to y carbon atoms. For example a (C₁₋₃)fluoroalkyl-thio group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. A representative example of a fluoroalkyl-thio group is trifluoromethyl-sulfanyl (F₃C—S—).

The term “(C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy” refers to a (C₁₋₄)alkoxy group as defined before containing one to four carbon atoms in which one hydrogen atom has been replaced with a (C₃₋₆)cycloalkyl group as defined before. A representative example of (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy groups is cyclopropylmethoxy.

The term “hydroxy-(C₁₋₄)alkoxy” refers to an alkoxy group as defined before containing one to four carbon atoms in which one hydrogen atom has been replaced with hydroxy. Representative examples of hydroxy-(C₁₋₄)alkoxy groups are 2-hydroxy-ethoxy and 2-hydroxy-propoxy (notably 2-hydroxy-ethoxy).

The term “dihydroxy-(C₁₋₄)alkoxy” refers to refers to an alkoxy group as defined before containing one to four carbon atoms in which two hydrogen atoms have been replaced with hydroxy. A representative example of a dihydroxy-(C₁₋₄)alkoxy group is 2,3-dihydroxy-propoxy.

The term “(C₁₋₄)alkoxy-(C₁₋₄)alkoxy” refers to an alkoxy group as defined before containing one to four carbon atoms in which one hydrogen atom has been replaced with a (C₁₋₄)alkoxy group as defined before. A representative example of a (C₁₋₄)alkoxy-(C₁₋₄)alkoxy group is 2-methoxy-ethoxy.

Further embodiments of the invention are presented hereafter:

2) A further embodiment of the invention relates to compounds according to embodiment 1), which are also compounds of formula (I_(E1)) wherein the stereocenter at position 2 of the oxazolidinone moiety is in absolute (S)-configuration:

3) A further embodiment of the invention relates to compounds according to embodiment 1), which are also compounds of formula (I_(E2)) wherein the stereocenter at position 2 of the oxazolidinone moiety is in absolute (R)-configuration:

4) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 5), wherein Y represents CHR¹, or CR¹R²; wherein each group forms a particular sub-embodiment.

5) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 5), wherein Y represents CH₂.

6) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 4), wherein, if present, R¹ represents methyl and, if present, R² represents methyl.

7) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein R³ represents Ar¹.

8) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein R³ represents Ar³—Z—Ar²—* wherein the asterisk indicates the bond that is attached to the rest of the molecule.

9) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), wherein

-   -   Ar¹ represents aryl which is unsubstituted, or mono-, di-, or         tri-substituted (notably mono-, or di-substituted), wherein the         substituents are independently selected from the group         consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, (C₁₋₃)fluoroalkyl-thio-,         and (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy (notably (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and         (C₁₋₃)fluoroalkoxy); or     -   Ar¹ represents heteroaryl which is unsubstituted, or mono-, di-,         or tri-substituted (notably mono-, or di-substituted), wherein         the substituents are independently selected from the group         consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy and (C₁₋₃)fluoroalkyl         (notably (C₁₋₄)alkyl).

10) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), wherein

-   -   Ar¹ represents aryl which is unsubstituted, or mono-, di-, or         tri-substituted (notably mono-, or di-substituted), wherein the         substituents are independently selected from the group         consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy, (C₁₋₃)fluoroalkyl, and         (C₁₋₃)fluoroalkoxy (notably (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy).

11) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), 9) or 10), wherein, in case Ar¹ represents aryl, said aryl is

-   -   phenyl which is unsubstituted, or mono-, di-, or tri-substituted         (notably mono-, or di-substituted), wherein the substituents are         independently selected from the group consisting of (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy,         (C₁₋₃)fluoroalkyl-thio-, and (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy         (notably (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl,         and (C₁₋₃)fluoroalkoxy); or     -   naphthyl (notably 2-naphthyl) which is unsubstituted, or mono-,         or di-substituted (notably unsubstituted or mono-substituted),         wherein the substituents are independently selected from the         group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably         (C₁₋₄)alkoxy); or     -   a phenyl ring fused to a 5- or 6-membered saturated or partially         unsaturated non-aromatic ring optionally containing 1 to 2         oxygen atoms (notably an indanyl, a benzo[1,3]dioxolyl, a         2,3-dihydrobenzofuranyl, or a 2,3-dihydro-benzo[1,4]dioxinyl         group) which is (preferably) unsubstituted, or mono-, or         di-substituted wherein the substituents are independently         selected from the group consisting of methyl, methoxy, and         halogen.

12) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), wherein

-   -   Ar¹ represents heteroaryl which is unsubstituted, or mono-, or         di-substituted, wherein the substituents are independently         selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy         and (C₁₋₃)fluoroalkyl (notably (C₁₋₄)alkyl).

13) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8) or 11), wherein Ar² represents phenyl (notably phenyl-1,4-diyl).

14) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8) or 11), wherein Ar² represents 5- to 6-membered heteroaryl (notably 6-membered heteroaryl).

15) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8), 11), 13) or 14), wherein Z represents a O.

16) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8), 11), 13) or 14), wherein Z represents a bond.

17) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8), 11), or 13) to 16), wherein

-   -   Ar³ represents phenyl which is unsubstituted, or mono-, di-, or         tri-substituted (notably unsubstituted or mono-substituted),         wherein the substituents are independently selected from the         group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably Ar³         represents unsubstituted phenyl); or     -   Ar³ represents 5- to 6-membered heteroaryl which is         unsubstituted, or mono-, di-, or tri-substituted (notably         unsubstituted or mono-substituted), wherein the substituents are         independently selected from the group consisting of (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy         (notably substituents are selected from (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, and (C₁₋₃)fluoroalkyl).

18) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8), 11), or 13) to 16), wherein

-   -   Ar³ represents 5- to 6-membered heteroaryl which is         unsubstituted, or mono-, di-, or tri-substituted (notably         unsubstituted or mono-substituted), wherein the substituents are         independently selected from the group consisting of (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy         (notably substituents are selected from (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, and (C₁₋₃)fluoroalkyl).

19) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8), 11), or 13) to 16), wherein

-   -   Ar³ represents phenyl which is unsubstituted, or mono-, di-, or         tri-substituted, (notably unsubstituted or mono-substituted)         wherein the substituents are independently selected from the         group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably Ar³         represents unsubstituted phenyl).

20) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein R³ represents

-   -   phenyl which is mono-, or di-substituted, wherein one         substituent is (C₁₋₄)alkoxy, or (C₁₋₃)fluoroalkoxy in position 4         of said phenyl and the other (if present) is selected from the         group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably halogen); or     -   Ar³—Z—Ar²—* wherein the asterisk indicates the bond that is         attached to the rest of the molecule; wherein         -   Ar² represents phenyl or 6-membered heteroaryl which are             substituted by Z and the rest of the molecule in a para             arrangement,         -   Z represents O, and         -   Ar³ represents phenyl or 5- to 6-membered heteroaryl wherein             the phenyl or 5- to 6-membered heteroaryl is independently             unsubstituted or mono-substituted, wherein the substituent             is independently selected from the group consisting of             (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and             (C₁₋₃)fluoroalkoxy (notably Ar³ represents unsubstituted             phenyl or 5- to 6-membered heteroaryl).

21) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 20), wherein

-   -   R⁴ represents aryl which is mono-, di-, or tri-substituted         (notably mono-, or di-substituted), wherein the substituents are         independently selected from the group consisting of (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy,         hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy (notably         substituents are selected from (C₁₋₄)alkyl, (C₁₋₄)alkoxy,         halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, and         hydroxy-(C₁₋₄)alkoxy); wherein, in the specific case wherein         said aryl is a bicyclic ring, the aryl may also be         unsubstituted; or     -   R⁴ represents heteroaryl which is mono-, di-, or tri-substituted         (notably mono-, or di-substituted), wherein the substituents are         independently selected from the group consisting of (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy,         hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy; (notably         substituents are selected from (C₁₋₄)alkyl, and (C₁₋₄)alkoxy)         wherein, in the specific case wherein said heteroaryl is a         bicyclic ring, the heteroaryl may also be unsubstituted.

22) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 21), wherein

-   -   R⁴ represents aryl which is mono-, di-, or tri-substituted         (notably mono-, or di-substituted), wherein the substituents are         independently selected from the group consisting of (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy,         hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy (notably         substituents are selected from (C₁₋₄)alkyl, (C₁₋₄)alkoxy,         halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, and         hydroxy-(C₁₋₄)alkoxy); wherein, in the specific case wherein         said aryl is a bicyclic ring, the aryl may also be         unsubstituted.

23) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 21), wherein

-   -   R⁴ represents heteroaryl which is mono-, di-, or tri-substituted         (notably mono-, or di-substituted), wherein the substituents are         independently selected from the group consisting of (C₁₋₄)alkyl,         (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy,         hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy; (notably         substituents are selected from (C₁₋₄)alkyl, and (C₁₋₄)alkoxy)         wherein, in the specific case wherein said heteroaryl is a         bicyclic ring, the heteroaryl may also be unsubstituted.

24) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 22), wherein, in case R⁴ represents aryl, said aryl is

-   -   phenyl which is mono-, di-, or tri-substituted (notably mono-,         or di-substituted), wherein the substituents are independently         selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy,         halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy,         hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy (notably         substituents are selected from (C₁₋₄)alkyl, (C₁₋₄)alkoxy,         halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, and         hydroxy-(C₁₋₄)alkoxy); or     -   naphthyl (notably 1-naphthyl) which is unsubstituted, or mono-,         or di-substituted (notably mono-substituted), wherein the         substituents are independently selected from the group         consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen,         (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably         (C₁₋₄)alkoxy); or     -   a phenyl ring fused to a 5- or 6-membered saturated or partially         unsaturated non-aromatic ring optionally containing 1 to 2         oxygen atoms (notably a 2,3-dihydro-benzo[1,4]dioxinyl group)         which is unsubstituted, or mono-, or di-substituted (notably         mono-substituted) wherein the substituents are independently         selected from the group consisting of methyl, methoxy, and         halogen (notably methoxy).

25) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 24), wherein R⁴ is at least mono-substituted, wherein said substituent is attached in ortho position to the point of attachment of R⁴ to the rest of the molecule; wherein, in case R⁴ represents a phenyl group, said substituent is preferably selected from the group consisting of (C₁₋₄)alkoxy, (C₁₋₃)fluoroalkoxy, and hydroxy-(C₁₋₄)alkoxy (notably (C₁₋₄)alkoxy); and, in case R⁴ represents a group different from phenyl, said substituent is preferably methoxy.

26) Another embodiment relates to compounds of formula (I) according to embodiment 1) which are also compounds of formula (II):

wherein Y¹ represents CH₂, CH(CH₃) or CH(CH₃)₂; R¹³ represents

wherein

-   -   R¹⁵ represents (C₁₋₄)alkyl or (C₁₋₃)fluoroalkyl;     -   V¹, V² and V⁴ are CH, and V³ is CR¹⁷, wherein optionally one or         two of V′, V², V³ and V⁴ may also be N; and     -   R¹⁷ is hydrogen or halogen; or     -   R¹⁵ represents phenyl or 5- to 6-membered heteroaryl, wherein         the phenyl or 5- to 6-membered heteroaryl is independently         unsubstituted, or mono-substituted, wherein the substituent is         selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy,         halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably R¹⁵         represents unsubstituted phenyl or 5- to 6-membered heteroaryl);         and one or two of V¹, V², V³ and V⁴ are CH or N and the         remaining are CH; and         R¹⁴ represents a group selected from the group consisting of:

wherein

-   -   W¹ represents CH and W² represents CR¹⁷ or N, or     -   W¹ represents N and W² represents CH;     -   R¹⁶ represents methyl, (C₁₋₃)alkoxy, halogen,         (C₁₋₂)fluoroalkoxy, or trifluoromethyl (notably methyl, methoxy,         ethoxy, fluoro, chloro, or trifluoromethyl);     -   R¹⁷ represents hydrogen, methyl or fluoro (notably hydrogen);         and     -   n represents the integer 1 or 2;         wherein characteristics described for compounds of formula (I),         notably those described in embodiments 2) to 5), apply mutatis         mutandis also to compounds of formula (II).

27) A further embodiment of the invention relates to compounds of formula (II) according to embodiments 26); wherein,

-   -   R¹⁵ represents (C₁₋₄)alkyl; (C₁₋₃)fluoroalkyl;     -   V¹, V² and V⁴ are CH, and V³ is CR¹⁸, wherein optionally one or         two of V¹, V², V³ and V⁴ may also be N; and     -   R¹⁸ is hydrogen or halogen.

28) A further embodiment of the invention relates to compounds of formula (II) according to embodiments 26) or 27); wherein,

-   -   R¹⁵ represents phenyl or 5- to 6-membered heteroaryl, wherein         the phenyl or 5- to 6-membered heteroaryl is independently         unsubstituted, or mono-substituted, wherein the substituent is         selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy,         halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy (notably R¹⁵         represents unsubstituted phenyl or 5- to 6-membered heteroaryl);         and     -   one or two of V¹, V², V³ and V⁴ are CH or N and the remaining         are CH.

29) A further embodiment of the invention relates to compounds of formula (II) according to any one of embodiments 26) to 28); wherein, R¹⁴ represents

wherein

-   -   W¹ represents CH and W² represents CR¹⁷ or N; or     -   W¹ represents N and W² represents CH;     -   R¹⁶ represents methyl, (C₁₋₃)alkoxy, halogen,         (C₁₋₂)fluoroalkoxy, or trifluoromethyl (notably methoxy or         ethoxy);     -   R¹⁷ represents hydrogen, methyl or fluoro (notably hydrogen);         wherein each combination of W¹, W², R¹⁶ and R¹⁷ constitutes a         particular sub-embodiment.

30) A further embodiment of the invention relates to compounds of formula (II) according to embodiment 29); wherein W¹ represents CH; W² represents CR¹⁷; R¹⁶ represents methoxy; and R¹⁷ represents hydrogen, or fluoro (notably hydrogen);

31) A further embodiment of the invention relates to compounds of formula (II) according to any one of embodiments 26) to 30); wherein, Y¹ represents CH₂.

32) A further embodiment of the invention relates to compounds of formula (II) according to any one of embodiments 26) to 30); wherein, Y¹ represents CH(CH₃).

33) A further embodiment of the invention relates to compounds of formula (II) according to any one of embodiments 26) to 30); wherein, Y¹ represents CH(CH₃)₂.

The compounds of formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. The compounds of formulae (I) and (II) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.

Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.

Any reference to compounds of formulae (I) or (II) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.

The term “pharmaceutically acceptable salts” refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to “Salt selection for basic drugs”, Int. J. Pharm. (1986), 33, 201-217.

34) Another embodiment relates to compounds of formula (I) according to embodiment 1) selected from the group consisting of:

-   3-(4-Chloro-3-trifluoromethyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(2-methyl-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(4-trifluoromethyl-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(3-methoxy-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(3-trifluoromethyl-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(3-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(4-fluoro-3-methyl-benzyl)-oxazolidin-4-one; -   3-(3-Chloro-4-fluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   3-(3-Chloro-2-fluoro-5-trifluoromethyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(2-methyl-3-trifluoromethyl-benzyl)-oxazolidin-4-one; -   3-(2-Chloro-5-trifluoromethyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(2-fluoro-5-trifluoromethyl-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(4-fluoro-3-trifluoromethyl-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(3-fluoro-4-trifluoromethyl-benzyl)-oxazolidin-4-one; -   3-(2-Chloro-3,6-difluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   3-(4-Chloro-3-fluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   3-(4-Chloro-2-fluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(2-fluoro-benzyl)-oxazolidin-4-one; -   3-(4-Chloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(2-fluoro-4-trifluoromethyl-benzyl)-oxazolidin-4-one; -   3-(2,6-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(3-methyl-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(4-fluoro-benzyl)-oxazolidin-4-one; -   3-(3,4-Difluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(4-methoxy-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-phenyl)-3-(2-methyl-5-trifluoromethyl-benzyl)-oxazolidin-4-one; -   3-(3,4-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   3-(2,4-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   3-(3-Chloro-4-methyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-trifluoromethyl-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(2-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(3-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   3-(3-Chloro-4-fluoro-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   3-(3-Chloro-2-fluoro-5-trifluoromethyl-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-fluoro-3-trifluoromethyl-benzyl)-oxazolidin-4-one; -   3-(4-Chloro-3-fluoro-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(2,4,6-trimethyl-benzyl)-oxazolidin-4-one; -   3-(2,4-Dichloro-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   3-(3-Chloro-4-methyl-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(2,6-dimethyl-benzyl)-oxazolidin-4-one; -   3-(2-Chloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   3-(2,5-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-naphthalen-2-ylmethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-propoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4-trifluoromethoxy-benzyl)-(R)-5-methyl-oxazolidin-4-one; -   3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-naphthalen-2-ylmethyl-oxazolidin-4-one; -   3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-(S)-5-methyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   3-Benzothiazol-2-ylmethyl-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; -   3-Benzothiazol-2-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-(S)-5-methyl-3-naphthalen-2-ylmethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4-trifluoromethoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; -   3-Benzooxazol-2-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(1-methyl-1H-benzoimidazol-2-ylmethyl)-oxazolidin-4-one; -   3-Benzo[1,3]dioxol-5-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-methoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; -   (R)-2-(2,6-Dimethoxy-phenyl)-5-methyl-3-(4-propoxy-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)-(R)-5-methyl-oxazolidin-4-one; -   3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-propoxy-benzyl)-oxazolidin-4-one; -   3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-ethoxy-benzyl)-(R)-5-methyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-3-(4-ethoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; -   3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethyl-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-difluoro-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2-methoxy-6-methyl-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   2-(2-Fluoro-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   2-(2-Chloro-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   2-(2-Methoxy-6-trifluoromethyl-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   3-Biphenyl-4-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-benzyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(6-phenoxy-pyridin-3-ylmethyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(5-phenoxy-pyridin-2-ylmethyl)-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(pyridin-2-yloxy)-benzyl]-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(pyrazin-2-yloxy)-benzyl]-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(6-methyl-pyridazin-3-yloxy)-benzyl]-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(thiazol-2-yloxy)-benzyl]-oxazolidin-4-one; -   2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(pyrimidin-2-yloxy)-benzyl]-oxazolidin-4-one; -   2-(2-Isopropoxy-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   2-(2-Ethoxy-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; -   2-[2-Methoxy-6-(2-methoxy-ethoxy)-phenyl]-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one;     and -   2-[2-(3-Hydroxy-propoxy)-6-methoxy-phenyl]-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one.

The compounds of formulae (I) and (II) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parental administration.

The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, “Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formulae (I) and (II).

For avoidance of any doubt, if compounds are described as useful for the prevention or treatment of certain diseases, such compounds are likewise suitable for use in the preparation of a medicament for the prevention or treatment of said diseases.

The compounds according to formulae (I) and (II) are useful for the prevention or treatment of diseases related to the orexin system.

Such diseases related to the orexin system may be selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of addictions (especially psychoactive substance use, abuse, seeking and reinstatement), of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.

In a sub-embodiment, such diseases related to the orexin system may be selected from the group consisting of sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders (notably all types of insomnias, especially primary insomnia).

In another sub-embodiment, such diseases related to the orexin system may be selected from the group consisting of cognitive dysfunctions that comprise deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.

In another sub-embodiment, such diseases related to the orexin system may be selected from the group consisting of eating disorders that comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.

In another sub-embodiment, such diseases related to the orexin system may be selected from the group consisting of all types of addictions (especially psychoactive substance use, abuse, seeking and reinstatement) that comprise all types of psychological or physical addictions and their related tolerance and dependence components.

Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa. Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance. Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake.

Sleep disorders include all types of parasomnias, insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.

Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness. Insomnia also include stress-related syndromes including post-traumatic stress disorders as well as other types and subtypes of anxiety disorders such as generalized anxiety, obsessive compulsive disorder, panic attacks and all types of phobic anxiety and avoidance.

Addictions may be defined as addiction to one or more rewarding stimuli, notably to one rewarding stimulus. Such rewarding stimuli may be of either natural or synthetic origin. Psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components.

Cognitive dysfunctions include deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.

Besides, any characteristics described in this invention for the compounds of formula (I) (whether for the compounds themselves, salts thereof, compositions containing the compounds or salts thereof, uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of formula (I_(E1)), formula (I_(E2)), and formula (II).

Preparation of Compounds of Formula (I):

A further aspect of the invention is a process for the preparation of compounds of formula (I). Compounds according to formula (I) of the present invention can be prepared according to the general sequence of reactions outlined in the schemes below wherein Y, R¹, R², R³, R⁴, R¹⁵, R¹⁶, R¹⁷, and R¹⁸ are as defined for formula (I) or (II). Other abbreviations used herein are explicitly defined, or are as defined in the experimental section. In some instances the generic groups Y, R¹, R², R³, R⁴, R¹⁵, R¹⁶, R¹⁷, and R¹⁸ might be incompatible with the assembly illustrated in the schemes below and so will require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example “Protective Groups in Organic Synthesis”, T. W. Greene, P. G. M. Wuts, Wiley-Interscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups as necessary are in place. The compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.

In general, all chemical transformations can be performed according to well-known standard methodologies as described in the literature or as described in the procedures below.

Oxazolidin-4-one derivatives (Y is CH₂ or CHR¹) of formula (I) may be prepared according to scheme 1.

Condensation of an amide (1) with an aldehyde (2) in the presence of an acid such PTSA in a Dean-Stark apparatus and in a solvent such as toluene provided the oxazolidin-4-one derivatives (3). Alkylation with a halide (4) in the presence of a strong base such as NaH in an aprotic solvent such as DMF yields the final compounds of formula (I).

Oxazolidin-4-one derivatives (Y is CR¹R²) of formula (I) may be prepared according to scheme 2.

Alternatively, condensation of cyanhydrin (5) with an aldehyde (2) in the presence of an strong acid such sulfuric acid in a mixture of Ac₂O and AcOH provides for example 5,5′-dimethyl-oxazolidin-4-one derivatives (6) (Stambach J.-P. et al, Heterocycles, 1997, 45, 9, 1825-1831). Alkylation with a halide (4) in the presence of a strong base such as NaH in an aprotic solvent such as DMF yields the compounds of formula (I).

Halides of formula R³—CH₂-L¹ and aldehydes of formula R⁴—CHO are commercially available, well known in the art, or readily available from commercially available precursors. Procedures to transform precursor functional groups into such required halides or aldehydes, such as reduction of carboxylic acids, esters, amides, nitriles; oxidation of alcohols; transformation into halides or equivalent activated alcohols (eg. methane-/toluene-sulphonates); or sequential metallation/formylation of aromatic halides are well known in the art (literature for precursors of heteroaryl-containing groups: see e.g. T. Eicher, S. Hauptmann “The chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications”, 2nd Edition 2003, Wiley, ISBN 978-3-527-30720-3; A. R. Katrizky, C. W. Rees, E. F. V. Scriven (Eds.) “Comprehensive Heterocyclic Chemistry II” 1996, Elsevier, ISBN 0-08-042072-9).

In some instances, substituents may also be introduced in a final step onto an appropriate (eg. phenolic) precursor molecule. The hydroxy group of such phenol precursor may be alkylated using standard procedures, or arylated using standard procedures such as the Ullmann reaction with halide derivatives of formula Ar³-L¹ in the presence of CuCl, 2,2,6,6-tetramethyl-heptane-3,5-dione and a base such as Cs₂CO₃ in an aprotic solvent such as NMP (WO2006/0173049).

The synthesis of some particular aldehydes of formula R⁴—CHO is described in the following schemes 3 to 6.

Methylation of commercially available 2,3-dihydro-benzo[1,4]dioxin-6-ol (7) with dimethyl sulfate gives 6-methoxy-2,3-dihydro-benzo[1,4]dioxine (8) (Guillaumet G. et al. Eur. J. Med. Chem. 1990, 25, 1, 45-51). Formylation with n-BuLi/DMF in the presence of TMDA in an aprotic solvent such as THF affords the aldehyde (9) (Guillaumet G. et al. J. Heterocyclic. Chem. 1989, 26, 1, 193-197).

Methylation of commercially benzo[1,3]dioxol-5-ol (10) with methyl iodide in the presence of a base such as K₂CO₃ in an aprotic solvent such as acetone affords 5-methoxy-benzo[1,3]dioxole (11) (Schuda P. F. et al, J. Org. Chem. 1987, 52, 10, 1972-1979). Formylation with n-BuLi/DMF in the presence of TMDA in an aprotic solvent such as THF affords aldehyde (12) (Guillaumet G. et al. J. Heterocyclic. Chem. 1989, 26, 1, 193-197).

Riemer-Tiemann reaction with CHCl₃ in aq. NaOH of the commercially available 7-hydroxyquinoline (13) gives the aldehyde (14). Methylation with dimethyl sulfate affords 7-methoxy-quinoline-8-carbaldehyde (15) (U.S. Pat. No. 4,342,771).

Benzooxazole and benzo[d]isoxazole aldehyde derivatives of formula R⁴—CHO may for instance be synthesised according to scheme 4.

Reaction of commercially available 3-amino-2,6-dihydroxy-benzoic acid methyl ester (16) with triethyl orthoacetate in the presence of PTSA gives the ester (17) (WO2006/069155). Methylation with dimethyl sulfate in the presence of a base such as K₂CO₃ in an aprotic solvent such as acetone affords compound (18). Reduction with LAH in an aprotic solvent such as THF gives the alcohol (19) which can be oxidized with MnO₂ in DCM to give 6-methoxy-2-methyl-benzooxazole-7-carbaldehyde (20).

Duff formylation of 3-methyl-benzo[d]isoxazol-6-ol (21) with urotropin in AcOH (Elkasaby M. A. et al Indian Journal of Chemistry 1980, 19B(7), 571-575) gives the aldehyde (22) (Kumari S. S. et al Indian Journal of Chemistry 1986, 25B(8), 870-871). Methylation with dimethyl sulfate affords 6-methoxy-3-methyl-benzo[d]isoxazole-7-carbaldehyde (23).

Further synthetic methods for the preparation of aldehydes R⁴—CHO are described below for the specific examples shown in schemes 5 and 6.

Formylation with n-BuLi/DMF in an aprotic solvent such as THF of the commercially available 3,5-dimethoxypyridine (21) affords 3,5-dimethoxy-pyridine-4-carbaldehyde (22) (U.S. Pat. No. 6,555,557).

Reaction of the commercially available 2-chloro-4-methoxy-pyridine-3-carbaldehyde (23) with NaOMe in MeOH affords 2,4-dimethoxy-pyridine-3-carbaldehyde (24).

Reaction of commercially 2-fluoro-6-methoxy-benzaldehyde (28) with NaOH in EtOH affords the aldehyde (29) (U.S. Pat. No. 4,367,234).

Vilsmeier-Haack reaction with POCl₃ in dry DMF of commercially available 1-fluoro-3,5-dimethoxy-benzene (30) gives a mixture of aldehyde (31) and aldehyde (32) with a ratio of about 1/9 (Stanjeck V. et al. Helvetica Chimica Acta 1998, 81, 9, 1596-1607).

Whenever the compounds of formula (I) or (II) are obtained in the form of mixtures of enantiomers, the enantiomers can be separated using methods known to the one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-O1 (R,R) (10 μm) column, a Daicel ChiralCel OD-H (5-10 μm) column, or a Daicel ChiralPak IA (10 μm) or AD-H (5 μm) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of an amine such as triethylamine, diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.

EXPERIMENTAL SECTION Abbreviations (as Used Herein)

Ac acetyl (as in Ac₂O=acetic acid anhydride; AcOH=acetic acid) aq. aqueous Bn benzyl BSA bovine serum albumine CHO Chinese hamster ovary conc. concentrated d day(s) DCM dichloromethane

DMF N,N-dimethylformamide

eq equivalent(s) ES electron spray ether diethyl ether EtOAc ethyl acetate FC flash chromatography on silica gel FCS foatal calf serum FLIPR fluorescent imaging plate reader h hour(s) HBSS Hank's balanced salt solution HEPES 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid HPLC high performance liquid chromatography LAH lithium aluminium hydride LC liquid chromatography M molar(ity) Me methyl MeCN acetonitrile MeOH methanol min minute(s) MS mass spectroscopy MW microwave n-BuLi n-butyllithium NMP 1-methyl-2-pyrrolidone prep. preparative PTSA (para-) p-toluenesulfonic acid RT room temperature sat. saturated t_(R) retention time TBS tert-Butyldimethylsilyl TFA trifluoroacetic acid THF tetrahydrofuran TMDA N,N,N′,N′-tetramethylethylenediamine

I-Chemistry

All temperatures are stated in ° C. Compounds are characterized by LC-MS (Finnigan Navigator with HP 1100 Binary Pump and DAD, column: 4.6×50 mm, Zorbax SB-AQ, 5 μm, 120 Å, using two conditions:

basic: eluent A: MeCN, eluent B: conc. NH₃ in water (1.0 mL/L), 5% to 95% CH₃CN; acidic: eluent A: MeCN, eluent B: TFA in water (0.4 mL/L), 5% to 95% CH₃CN), t_(R) is given in min; by TLC (TLC-plates from Merck, Silica gel 60 F_(F254)); or by melting point. Compounds are purified by column chromatography on silica gel or by preparative HPLC (column: X-terra RP18, 50×19 mm, 5 μm, gradient: 10-95% MeCN in water containing 0.5% of formic acid).

The following examples illustrate the preparation of pharmacologically active compounds of the invention but do not at all limit the scope thereof. All example compounds have been synthesized in racemic form or as epimers without control of the stereocenter in position 2 of the oxazolidinone moiety.

A.1 Synthesis of oxazolidin-4-one derivatives A.1.1 Synthesis of 2-aryl-oxazolidin-4-one derivatives (Y═CH₂ or CHR¹) (general procedure)

A mixture of the respective aldehyde derivative R⁴—CHO (1.1 eq), the respective amide (1.0 eq), and PTSA (0.01 eq) in dry toluene (60 mL/20 mmol) is stirred at reflux in a Dean-Stark apparatus for 12 h. After removal of the toluene, the residue is dissolved in DCM, washed with water and brine, dried over MgSO₄ and concentrated in vacuo to give a crude oil. FC (EtOAc) gives the desired 4-aryl-oxazolidin-4-one derivative.

2-(2,6-Dimethoxy-phenyl)-oxazolidin-4-one

prepared by reaction of 2,6-dimethoxybenzaldehyde with glycolamide; LC-MS: t_(R)=0.41 min; [M+H]⁺=224.31.

2-(2-Ethoxy-phenyl)-oxazolidin-4-one

prepared by reaction of 2-ethoxybenzaldehyde with glycolamide; LC-MS: t_(R)=0.75 min; [M+H]⁺=207.97.

2-(2,6-Dimethoxy-phenyl)-(S)-5-methyl-oxazolidin-4-one

prepared by reaction of 2,6-dimethoxybenzaldehyde with (S)-(−)-2-hydroxypropionamide; LC-MS: t_(R)=0.45 min; [M+H]⁺=238.28.

2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one

prepared by reaction of 2,6-dimethoxybenzaldehyde with (R)-(+)-lactamide; LC-MS: t_(R)=0.45 min; [M+H]⁺=238.21.

A.1.2 Synthesis of 2-aryl-oxazolidin-4-one derivatives (Y═CR¹R²)

2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one

To a mixture of acetone cyanhydrin (851 mg), 2,6-dimethoxybenzaldehyde (1.58 g) in AcOH (10 mL) is added at 10° C. dropwise H₂SO₄ (1 mL) and Ac₂O (0.5 mL). The reaction mixture is stirred at 10° C. for 40 min and then 10 min at RT. The reaction mixture is poured into cracked ice and extracted three times with ether. The combined organic extracts are washed with 10% aq. NaHCO₃, dried (Na₂SO₄), filtered and concentrated to yield a crude oil. FC (EtOAc) gives the title compound as a brown oil (1.3 g, 52%). LC-MS: t_(R)=0.47 min; [M+H]⁺=252.25.

A.2 Preparation of Examples (Method A)

To a cold (0° C.) solution of the respective 2-substituted oxazolidin-4-one derivative (1.0 eq) in DMF (1 mL/0.1 mmol) is added NaH (50% in mineral oil) (2 eq). The reaction mixture is stirred at RT for 30 min under inert atmosphere. Then the respective halide (1 eq) is added and the reaction mixture is stirred at 70° C. for 1.5 h and then 12 h at RT. The products are directly purified by prep. HPLC to provide the final compounds.

The Examples given in table 1 were synthesized according to method A above:

TABLE 1 Example Name [M + H]⁺ t_(R) 1 3-(4-Chloro-3-trifluoromethyl-benzyl)-2-(2-ethoxy- 399.97 1.11 phenyl)-oxazolidin-4-one 2 2-(2-Ethoxy-phenyl)-3-(2-methyl-benzyl)- 311.96 0.98 oxazolidin-4-one 3 2-(2-Ethoxy-phenyl)-3-(4-trifluoromethyl-benzyl)- 365.97 1.09 oxazolidin-4-one 4 2-(2-Ethoxy-phenyl)-3-(3-methoxy-benzyl)- 327.98 0.95 oxazolidin-4-one 5 2-(2-Ethoxy-phenyl)-3-(3-trifluoromethyl-benzyl)- 366.01 1.08 oxazolidin-4-one 6 2-(2-Ethoxy-phenyl)-3-(4-trifluoromethoxy-benzyl)- 381.97 1.09 oxazolidin-4-one 7 2-(2-Ethoxy-phenyl)-3-(3-trifluoromethoxy-benzyl)- 382.02 1.09 oxazolidin-4-one 8 2-(2-Ethoxy-phenyl)-3-(4-fluoro-3-methyl-benzyl)- 329.97 1.00 oxazolidin-4-one 9 3-(3-Chloro-4-fluoro-benzyl)-2-(2-ethoxy-phenyl)- 349.96 1.07 oxazolidin-4-one 10 3-(3-Chloro-2-fluoro-5-trifluoromethyl-benzyl)-2-(2- 417.90 1.13 ethoxy-phenyl)-oxazolidin-4-one 11 2-(2-Ethoxy-phenyl)-3-(2-methyl-3-trifluoromethyl- 380.04 1.11 benzyl)-oxazolidin-4-one 12 3-(2-Chloro-5-trifluoromethyl-benzyl)-2-(2-ethoxy- 399.96 1.12 phenyl)-oxazolidin-4-one 13 2-(2-Ethoxy-phenyl)-3-(2-fluoro-5-trifluoromethyl- 384 1.09 benzyl)-oxazolidin-4-one 14 2-(2-Ethoxy-phenyl)-3-(4-fluoro-3-trifluoromethyl- 384 1.09 benzyl)-oxazolidin-4-one 15 2-(2-Ethoxy-phenyl)-3-(3-fluoro-4-trifluoromethyl- 384 1.10 benzyl)-oxazolidin-4-one 16 3-(2-Chloro-3,6-difluoro-benzyl)-2-(2-ethoxy- 367.96 1.07 phenyl)-oxazolidin-4-one 17 3-(4-Chloro-3-fluoro-benzyl)-2-(2-ethoxy-phenyl)- 349.95 1.08 oxazolidin-4-one 18 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2-ethoxy- 415.95 1.12 phenyl)-oxazolidin-4-one 19 3-(4-Chloro-2-fluoro-benzyl)-2-(2-ethoxy-phenyl)- 349.94 1.08 oxazolidin-4-one 20 2-(2-Ethoxy-phenyl)-3-(2-fluoro-benzyl)-oxazolidin- 315.97 1.04 4-one 21 3-(4-Chloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin- 331.94 1.07 4-one 22 2-(2-Ethoxy-phenyl)-3-(2-fluoro-4-trifluoromethyl- 384.02 1.10 benzyl)-oxazolidin-4-one 23 3-(2,6-Dichloro-benzyl)-2-(2-ethoxy-phenyl)- 365.93 1.09 oxazolidin-4-one 24 2-(2-Ethoxy-phenyl)-3-(3-methyl-benzyl)- 311.96 0.99 oxazolidin-4-one 25 2-(2-Ethoxy-phenyl)-3-(4-fluoro-benzyl)-oxazolidin- 315.98 0.97 4-one 26 3-(3,4-Difluoro-benzyl)-2-(2-ethoxy-phenyl)- 333.97 1.05 oxazolidin-4-one 27 2-(2-Ethoxy-phenyl)-3-(4-methoxy-benzyl)- 327.99 0.96 oxazolidin-4-one 28 2-(2-Ethoxy-phenyl)-3-(5-methyl-2-trifluoromethyl- 380.02 1.11 benzyl)-oxazolidin-4-one 29 3-(3,4-Dichloro-benzyl)-2-(2-ethoxy-phenyl)- 365.93 1.10 oxazolidin-4-one 30 3-(2,4-Dichloro-benzyl)-2-(2-ethoxy-phenyl)- 365.95 1.11 oxazolidin-4-one 31 3-(3-Chloro-4-methyl-benzyl)-2-(2-ethoxy-phenyl)- 345.95 1.09 oxazolidin-4-one 32 2-(2,6-Dimethoxy-phenyl)-3-(4-trifluoromethyl- 381.99 1.06 benzyl)-oxazolidin-4-one 33 2-(2,6-Dimethoxy-phenyl)-3-(2-trifluoromethoxy- 397.97 1.07 benzyl)-oxazolidin-4-one 34 2-(2,6-Dimethoxy-phenyl)-3-(4-trifluoromethoxy- 397.97 1.07 benzyl)-oxazolidin-4-one 35 2-(2,6-Dimethoxy-phenyl)-3-(3-trifluoromethoxy- 397.97 1.07 benzyl)-oxazolidin-4-one 36 3-(3-Chloro-4-fluoro-benzyl)-2-(2,6-dimethoxy- 365.95 1.05 phenyl)-oxazolidin-4-one 37 3-(3-Chloro-2-fluoro-5-trifluoromethyl-benzyl)-2- 433.90 1.10 (2,6-dimethoxy-phenyl)-oxazolidin-4-one 38 2-(2,6-Dimethoxy-phenyl)-3-(4-fluoro-3- 400.02 1.06 trifluoromethyl-benzyl)-oxazolidin-4-one 39 3-(4-Chloro-3-fluoro-benzyl)-2-(2,6-dimethoxy- 365.96 1.05 phenyl)-oxazolidin-4-one 40 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6- 431.91 1.10 dimethoxy-phenyl)-oxazolidin-4-one 41 2-(2,6-Dimethoxy-phenyl)-3-(2,4,6-trimethyl- 356.04 1.01 benzyl)-oxazolidin-4-one 42 3-(2,4-Dichloro-benzyl)-2-(2,6-dimethoxy-phenyl)- 381.91 1.01 oxazolidin-4-one 43 3-(3-Chloro-4-methyl-benzyl)-2-(2,6-dimethoxy- 341.99 1.05 phenyl)-oxazolidin-4-one 44 2-(2,6-Dimethoxy-phenyl)-3-(2,6-dimethyl-benzyl)- 341.94 1.16 oxazolidin-4-one 45 3-(2-Chloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin- 331.92 1.06 4-one 46 3-(2,5-Dichloro-benzyl)-2-(2-ethoxy-phenyl)- 365.95 1.11 oxazolidin-4-one 47 2-(2,6-Dimethoxy-phenyl)-3-(4-phenoxy-benzyl)- 406.13 0.78 oxazolidin-4-one 48 2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4- 416.13 0.76 trifluoromethoxy-benzyl)-oxazolidin-4-one 49 3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy- 380.17 0.70 phenyl)-oxazolidin-4-one 50 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4- 433.78 0.80 phenoxy-benzyl)-oxazolidin-4-one 51 2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-(4- 420.19 0.79 phenoxy-benzyl)-oxazolidin-4-one 52 3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy- 394.16 0.72 phenyl)-(R)-5-methyl-oxazolidin-4-one 53 2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3- 378.29 0.75 naphthalen-2-ylmethyl-oxazolidin-4-one 54 2-(2,6-Dimethoxy-phenyl)-3-(4-propoxy-benzyl)- 372.20 0.74 oxazolidin-4-one 55 2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4- 430.14 0.77 trifluoromethoxy-benzyl)-(R)-5-methyl-oxazolidin-4- one 56 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6- 446.14 0.79 dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one 57 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3- 392.24 0.76 naphthalen-2-ylmethyl-oxazolidin-4-one 58 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6- 460.11 0.81 dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one 59 2-(2,6-Dimethoxy-phenyl)-(S)-5-methyl-3-(4- 420.22 0.79 phenoxy-benzyl)-oxazolidin-4-one 60 2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)- 372.22 0.72 oxazolidin-4-one 61 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4- 426.24 0.78 trifluoromethoxy-benzyl)-oxazolidin-4-one 62 3-Benzothiazol-2-ylmethyl-2-(2,6-dimethoxy- 385.12 0.68 phenyl)-(R)-5-methyl-oxazolidin-4-one 63 2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-(4- 412.22 0.77 trifluoromethoxy-benzyl)-oxazolidin-4-one 64 3-Benzothiazol-2-ylmethyl-2-(2,6-dimethoxy- 399.21 0.70 phenyl)-5,5-dimethyl-oxazolidin-4-one 65 3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6- 384.28 0.74 dimethoxy-phenyl)-oxazolidin-4-one 66 2-(2,6-Dimethoxy-phenyl)-(S)-5-methyl-3- 378.19 0.75 naphthalen-2-ylmethyl-oxazolidin-4-one 67 2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4- 444.13 0.79 trifluoromethoxy-benzyl)-5,5-dimethyl-oxazolidin-4- one 68 3-Benzooxazol-2-ylmethyl-2-(2,6-dimethoxy- 383.20 0.67 phenyl)-5,5-dimethyl-oxazolidin-4-one 69 3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy- 408.19 0.74 phenyl)-5,5-dimethyl-oxazolidin-4-one 70 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(1- 396.22 0.51 methyl-1H-benzoimidazol-2-ylmethyl)-oxazolidin-4- one 71 3-Benzo[1,3]dioxol-5-ylmethyl-2-(2,6-dimethoxy- 385.73 0.69 phenyl)-5,5-dimethyl-oxazolidin-4-one 72 2-(2,6-Dimethoxy-phenyl)-3-(4-methoxy-benzyl)- 372.22 0.69 5,5-dimethyl-oxazolidin-4-one 73 2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-(4- 385.83 0.76 propoxy-benzyl)-oxazolidin-4-one 74 2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)- 385.82 0.74 (R)-5-methyl-oxazolidin-4-one 75 3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6- 398.27 0.75 dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one 76 2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)- 400.27 0.75 5,5-dimethyl-oxazolidin-4-one 77 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4- 400.27 0.77 propoxy-benzyl)-oxazolidin-4-one 78 3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6- 412.23 0.76 dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one 79 2-(2,6-Dimethoxy-phenyl)-3-(4-ethoxy-benzyl)-(r)- 372.23 0.71 5-methyl-oxazolidin-4-one 80 2-(2,6-Dimethoxy-phenyl)-3-(4-ethoxy-benzyl)-5,5- 385.76 0.73 dimethyl-oxazolidin-4-one 81 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6- 428.09 0.86 dimethyl-phenyl)-5,5-dimethyl-oxazolidin-4-one 82 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6- 436.07 0.83 difluoro-phenyl)-5,5-dimethyl-oxazolidin-4-one 83 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2- 443.31 0.86 methoxy-6-methyl-phenyl)-5,5-dimethyl-oxazolidin- 4-one 84 2-(2-Fluoro-6-methoxy-phenyl)-5,5-dimethyl-3-(4- 422.20 0.82 phenoxy-benzyl)-oxazolidin-4-one 85 2-(2-Chloro-6-methoxy-phenyl)-5,5-dimethyl-3-(4- 438.19 0.83 phenoxy-benzyl)-oxazolidin-4-one 86 2-(2-Methoxy-6-trifluoromethyl-phenyl)-5,5- 472.25 0.85 dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one 87 3-Biphenyl-4-ylmethyl-2-(2,6-dimethoxy-phenyl)- 417.77 0.81 5,5-dimethyl-oxazolidin-4-one 88 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4- 442.17 0.81 trifluoromethylsulfanyl-benzyl)-oxazolidin-4-one 89 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(6- 435.24 0.73 phenoxy-pyridin-3-ylmethyl)-oxazolidin-4-one

Example 90 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(5-phenoxy-pyridin-2-ylmethyl)-oxazolidin-4-one

This compound has been prepared according to method A above using 2-chloromethyl-5-phenoxy-pyridine hydrochloride (prepared using the methods given in Kawasuji T. et al, Bioorganic & Medicinal Chemistry 2006, 14, 8430-8445 and WO2007/099317) as halide. LC-MS: t_(R)=0.72 min; [M+H]⁺=435.16.

A.3 Preparation of Examples (Method B) A.3.1 Preparation of 2-(2,6-dimethoxy-phenyl)-3-(4-hydroxy-benzyl)-5,5-dimethyl-oxazolidin-4-one

This compound has been prepared according to method A above using (4-bromomethyl-phenoxy)-tert-butyl-diphenyl-silane (prepared using the methods given in Petit G. R. et al, Journal of Medicinal Chemistry 2002, 45, 12, 2534-2542) as halide. LC-MS: t_(R)=0.58 min; [M+H]⁺=358.20.

A.3.2 Preparation of Examples (Method B)

The examples given in table 2 have been prepared from 2-(2,6-dimethoxy-phenyl)-3-(4-hydroxy-benzyl)-5,5-dimethyl-oxazolidin-4-one via Ullmann reaction with an appropriate heteroaryl halide derivatives of formula R¹⁵-L¹ in the presence of CuCl, 2,2,6,6-tetramethyl-heptane-3,5-dione and a base such as Cs₂CO₃ in an aprotic solvent such as NMP (WO2006/0173049).

TABLE 2 Example Name [M + H]⁺ t_(R) 91 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl- 435.28 0.73 3-[4-(pyridin-2-yloxy)-benzyl]- oxazolidin-4-one 92 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl- 436.31 0.72 3-[4-(pyrazin-2-yloxy)-benzyl]- oxazolidin-4-one 93 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl- 449.71 0.64 3-[4-(6-methyl-pyridazin-3-yloxy)- benzyl]-oxazolidin-4-one 94 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl- 441.18 0.73 3-[4-(thiazol-2-yloxy)-benzyl]- oxazolidin-4-one 95 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl- 436.24 0.68 3-[4-(pyrimidin-2-yloxy)-benzyl]- oxazolidin-4-one

A.4 Preparation of Examples (Method C) A.4.1 Preparation of 2-(2-hydroxy-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one A.4.1.1. Preparation of 2-(2-benzyloxy-6-methoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one

A mixture of commercially available 2-hydroxyisobutyramide (638.5 mg, 3 eq), 2-benzyloxy-6-methoxy-benzaldehyde (500 mg) (Katritzky A. R. et al ARKIVOC 2001, 2, 3, 3-12) is heated at 240° C. for 5 min using microwave irradiation (Lecolier S. et al Chimica Therapeutica 1969, 4,6, 437-445). The crude oil is poured into water and extracted with DCM. The combined organic extracts are dried (MgSO₄), filtered and concentrated to yield a crude oil. FC (EN n-heptane: 1/1 to 1/0) gives the title compound as a yellow solid (0.41 g, 61%); LC-MS: t_(R)=0.65 min; [M+H]⁺=328.22.

A.4.1.2. Preparation of 2-(2-hydroxy-6-methoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one

To a cold (0° C.) solution of 2-(2-benzyloxy-6-methoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one (410 mg) in dry DMF (5 mL) is added portionwise NaH 90% (45 mg, 1.5 eq). The reaction mixture is stirred for 15 min at 0° C. and then commercially available 1-(bromomethyl)-4-phenoxybenzene (395 mg, 1.2 eq) is added and the reaction mixture is stirred at RT for 1 h. The reaction mixture is poured into water, extracted with DCM. The combined organic extracts are dried (MgSO₄), filtered and concentrated to yield a crude oil. FC (EN n-heptane: 0/1 to 4/6) gives 2-(2-benzyloxy-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one as a colorless oil (0.495 g, 77%); LC-MS: t_(R)=0.88 min; [M+H]⁺=510.33.

Hydrogenation of this intermediate over Pd(OH)₂ at normal pressure in EtOH gives the title compound as a white solid (388 mg, 93%); LC-MS: t_(R)=0.75 min; [M+H]⁺=420.17.

A.4.2. Preparation of Examples (Method C)

To a mixture of 2-(2-hydroxy-6-methoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one (0.05 mmol), Cs₂CO₃ (0.065 mmol) in dry DMF (0.1 mL) is added dropwise the appropriate halide alkylating agent (0.1 mmol) (e.g. 1-bromo-3-hydroxy-propane, 2-methoxy-ethylbromide, 2-bromopropane, ethylbromide) in dry DMF (0.1 mL). The reaction mixture is stirred at 90° C. for 30 min. The products are directly purified by prep. HPLC to provide the final compound.

The Examples given in table 3 were synthesized according to method C above:

TABLE 3 Example Name [M + H]⁺ t_(R) 96 2-(2-Isopropoxy-6-methoxy-phenyl)- 462.24 1.04 5,5-dimethyl-3-(4-phenoxy-benzyl)- oxazolidin-4-one 97 2-(2-Ethoxy-6-methoxy-phenyl)-5,5- 448.19 1.01 dimethyl-3-(4-phenoxy-benzyl)- oxazolidin-4-one 98 2-[2-Methoxy-6-(2-methoxy-ethoxy)- 478.16 0.97 phenyl]-5,5-dimethyl-3-(4-phenoxy- benzyl)-oxazolidin-4-one 99 2-[2-(3-Hydroxy-propoxy)-6-methoxy- 478.15 0.90 phenyl]-5,5-dimethyl-3-(4-phenoxy- benzyl)-oxazolidin-4-one

II-Biological Assays In Vitro Assay

The orexin receptor antagonistic activity of the compounds of formula (I) is determined in accordance with the following experimental method.

Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 μg/ml G418, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% heat inactivated fetal calf serum (FCS). The cells are seeded at 20′000 cells/well into 384-well black clear bottom sterile plates (Greiner). The seeded plates are incubated overnight at 37° C. in 5% CO₂.

Human orexin-A as an agonist is prepared as 1 mM stock solution in MeOH:water (1:1), diluted in HBSS containing 0.1% bovine serum albumin (BSA), NaHCO₃: 0.375 g/l and 20 mM HEPES for use in the assay at a final concentration of 3 nM.

Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 384-well plates using DMSO followed by a transfer of the dilutions into in HBSS containing 0.1% bovine serum albumin (BSA), NaHCO₃: 0.375 g/l and 20 mM HEPES. On the day of the assay, 50 μl of staining buffer (HBSS containing 1% FCS, 20 mM HEPES, NaHCO₃: 0.375 g/l, 5 mM probenecid (Sigma) and 3 μM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well. The 384-well cell-plates are incubated for 50 min at 37° C. in 5% CO₂ followed by equilibration at rt for 30-120 min before measurement.

Within the Fluorescent Imaging Plate Reader (FLIPR Tetra, Molecular Devices), antagonists are added to the plate in a volume of 10 μl/well, incubated for 10 min and finally 10 μl/well of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 3 nM orexin-A with vehicle in place of antagonist. For each antagonist, the IC₅₀ value (the concentration of compound needed to inhibit 50% of the agonistic response) is determined and normalized using the obtained IC₅₀ value of a on-plate reference compound. Optimized conditions were achieved by adjustment of pipetting speed and cell splitting regime. The calculated IC₅₀ values of the compounds may fluctuate depending on the daily cellular assay performance. Fluctuations of this kind are known to those skilled in the art.

Antagonistic activities of exemplified compounds are displayed in Table 1.

TABLE 1 OX₁ IC₅₀ OX₂ IC₅₀ OX₁ IC₅₀ OX₂ IC₅₀ OX₁ IC₅₀ OX₂ IC₅₀ Ex. (nM) (nM) Ex. (nM) (nM) Ex. (nM) (nM) 18 8794   26 1 6487 263 13 >10000 290 37 162 477 2 >10000 223 14 >10000 169 40 198  29 3 9991 230 15 >10000 359 47 1184   68 4 >10000 705 16 590 3813 50  28*  58* 5 >10000 462 17 9370 627 51 220  25 6 >10000 55 19 9598 586 57    5*²   151*² 7 6806 74 20 >10000 262 61  29 160 8 9167 584 21 >10000 696 67   25*²   322*² 9 8736 79 22 >10000 839 70  65 1298  10 8409 693 23 1844 787 76 114 193 11 5408 385 24 >10000 363 80 139 1937  12 4044 590 68 2936 508 25 >10000    199 38 1382 730 53 47 65 26 >10000    652 39 4105 795 54 1710 81 27 >10000    353 41 542 681 55 178 108 28 8021  661 42 1489 376 56 164 111 29 >10000    696 43 553 349 58 25 133 30 3045  844 44 1758 467 59 2134 150 31 7596  634 45 1738 870 60 3242 159 32 >10000    413 46 788 1522 62 2867 193 33 >10000    225 47 1184 68 63 260 216 34 6474  298 48 1352 99 64 411 222 35 2889  618 49 2991 113 65 6325 243 36 1340  632 52 726 41 66 421 266 69 187 928 82 336 110 92 1212 3059 71 150 1664  83 133 69 93 1198 8331 72 188 2267  84 421 46 95 2990 7262 73 581  86 85 204 37 96 10 120 74 1208   95 86 2177 65 97 25 62 75 1763  123 87 64 1086 98 345 366 77 114 484 88 120 298 99 80 150 78 472 620 89 139 212 81 920 88 79 830 864 90 413 236 91 110 443 Ex. = Compound of Example *geomean from n = 5 values *²geomean from n = 2 values 

1. A compound of formula (I)

wherein Y represents CH₂, CHR¹, or CR¹R²; wherein R¹ and R² independently represent (C₁₋₄)alkyl; R³ represents Ar¹ or Ar³—Z—Ar²—* wherein the asterisk indicates the bond that is attached to the rest of the molecule; wherein Ar¹ represents aryl or heteroaryl, wherein the aryl or heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, (C₁₋₃)fluoroalkyl-thio-, and (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy; Ar² represents phenyl or 5- to 6-membered heteroaryl; Z represents a bond, O, or —CH₂—O—* wherein the asterisk indicates the bond that is attached to Ar²; Ar³ represents phenyl or 5- to 6-membered heteroaryl wherein the phenyl or 5- to 6-membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; and R⁴ represents aryl or heteroaryl, wherein the aryl or heteroaryl is independently mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy; wherein, in the specific case wherein said aryl or heteroaryl is a bicyclic ring, the aryl or heteroaryl may also be unsubstituted; with the exception of the following compounds: 2-(2-bromophenyl)-3-[(4-methoxyphenyl)methyl]-4-oxazolidinone; 2-(2-bromophenyl)-3-{[4-(trifluoromethyl)phenyl]methyl}-4-oxazolidinone; 2-(2-bromophenyl)-3-(phenylmethyl)-4-oxazolidinone; and 2-(4-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]-5-methyl-4-oxazolidinone; in a free or a pharmaceutically acceptable salt.
 2. The compound according to claim 1; wherein Y represents CHR¹, or CR¹R²; in a free or a pharmaceutically acceptable salt.
 3. The compound according to claim 1; wherein Ar¹ represents aryl which is unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, (C₁₋₃)fluoroalkyl-thio-, and (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy; or Ar¹ represents heteroaryl which is unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy and (C₁₋₃)fluoroalkyl; in a free or a pharmaceutically acceptable salt.
 4. The compound according to claim 1; wherein, in case Ar¹ represents aryl, said aryl is phenyl which is unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, (C₁₋₃)fluoroalkyl-thio-, and (C₃₋₆)cycloalkyl-(C₁₋₄)alkoxy; or naphthyl which is unsubstituted, or mono-, or di-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; or a phenyl ring fused to a 5- or 6-membered saturated or partially unsaturated non-aromatic ring optionally containing 1 to 2 oxygen atoms which is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from the group consisting of methyl, methoxy, and halogen; in a free or a pharmaceutically acceptable salt.
 5. The compound according to claim 1; wherein Z represents a O; in a free or a pharmaceutically acceptable salt.
 6. The compound according to claim 1; wherein Ar³ represents phenyl which is unsubstituted, or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; or Ar³ represents 5- to 6-membered heteroaryl which is unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; in a free or a pharmaceutically acceptable salt.
 7. The compound according to claim 1; wherein R³ represents phenyl which is mono-, or di-substituted, wherein one substituent is (C₁₋₄)alkoxy, or (C₁₋₃)fluoroalkoxy in position 4 of said phenyl and the other (if present) is selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; or Ar³—Z—Ar²—* wherein the asterisk indicates the bond that is attached to the rest of the molecule; wherein Ar² represents phenyl or 6-membered heteroaryl which are substituted by Z and the rest of the molecule in a para arrangement, Z represents O, and Ar³ represents phenyl or 5- to 6-membered heteroaryl wherein the phenyl or 5- to 6-membered heteroaryl is independently unsubstituted or mono-substituted, wherein the substituent is independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; in a free or a pharmaceutically acceptable salt.
 8. The compound according to claim 1; wherein R⁴ represents aryl which is mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy; wherein, in the specific case wherein said aryl is a bicyclic ring, the aryl may also be unsubstituted; or R⁴ represents heteroaryl which is mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy; wherein, in the specific case wherein said heteroaryl is a bicyclic ring, the heteroaryl may also be unsubstituted; in a free or a pharmaceutically acceptable salt.
 9. The compound according to claim 1; wherein, in case R⁴ represents aryl, said aryl is phenyl which is mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, (C₁₋₃)fluoroalkoxy, hydroxy-(C₁₋₄)alkoxy, and (C₁₋₄)alkoxy-(C₁₋₄)alkoxy; or naphthyl which is unsubstituted, or mono-, or di-substituted, wherein the substituents are independently selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; or a phenyl ring fused to a 5- or 6-membered saturated or partially unsaturated non-aromatic ring optionally containing 1 to 2 oxygen atoms which is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from the group consisting of methyl, methoxy, and halogen; in a free or a pharmaceutically acceptable salt.
 10. A compound of formula (I) according to claim 1 which is also a compound of formula (II)

wherein Y¹ represents CH₂, CH(CH₃) or CH(CH₃)₂; R¹³ represents

wherein R¹⁵ represents (C₁₋₄)alkyl or (C₁₋₃)fluoroalkyl; V¹, V² and V⁴ are CH, and V³ is CR¹⁷, wherein optionally one or two of V¹, V², V³ and V⁴ may also be N; and R¹⁷ is hydrogen or halogen; or R¹⁵ represents phenyl or 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl is independently unsubstituted, or mono-substituted, wherein the substituent is selected from the group consisting of (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, (C₁₋₃)fluoroalkyl, and (C₁₋₃)fluoroalkoxy; and one or two of V¹, V², V³ and V⁴ are CH or N and the remaining are CH; and R¹⁴ represents a group selected from the group consisting of:

wherein W¹ represents CH and W² represents CR¹⁷ or N, or W¹ represents N and W² represents CH; R¹⁶ represents methyl, (C₁₋₃)alkoxy, halogen, (C₁₋₂)fluoroalkoxy, or trifluoromethyl; R¹⁷ represents hydrogen, methyl or fluoro; and n represents the integer 1 or 2; in a free or a pharmaceutically acceptable salt.
 11. The compound according to claim 1 selected from the group consisting of: 3-(4-Chloro-3-trifluoromethyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(2-methyl-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(4-trifluoromethyl-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(3-methoxy-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(3-trifluoromethyl-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(3-trifluoromethoxy-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(4-fluoro-3-methyl-benzyl)-oxazolidin-4-one; 3-(3-Chloro-4-fluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 3-(3-Chloro-2-fluoro-5-trifluoromethyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(2-methyl-3-trifluoromethyl-benzyl)-oxazolidin-4-one; 3-(2-Chloro-5-trifluoromethyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(2-fluoro-5-trifluoromethyl-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(4-fluoro-3-trifluoromethyl-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(3-fluoro-4-trifluoromethyl-benzyl)-oxazolidin-4-one; 3-(2-Chloro-3,6-difluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 3-(4-Chloro-3-fluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 3-(4-Chloro-2-fluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(2-fluoro-benzyl)-oxazolidin-4-one; 3-(4-Chloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(2-fluoro-4-trifluoromethyl-benzyl)-oxazolidin-4-one; 3-(2,6-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(3-methyl-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(4-fluoro-benzyl)-oxazolidin-4-one; 3-(3,4-Difluoro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(4-methoxy-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-phenyl)-3-(2-methyl-5-trifluoromethyl-benzyl)-oxazolidin-4-one; 3-(3,4-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 3-(2,4-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 3-(3-Chloro-4-methyl-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-trifluoromethyl-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(2-trifluoromethoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(3-trifluoromethoxy-benzyl)-oxazolidin-4-one; 3-(3-Chloro-4-fluoro-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 3-(3-Chloro-2-fluoro-5-trifluoromethyl-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-fluoro-3-trifluoromethyl-benzyl)-oxazolidin-4-one; 3-(4-Chloro-3-fluoro-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(2,4,6-trimethyl-benzyl)-oxazolidin-4-one; 3-(2,4-Dichloro-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 3-(3-Chloro-4-methyl-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(2,6-dimethyl-benzyl)-oxazolidin-4-one; 3-(2-Chloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 3-(2,5-Dichloro-benzyl)-2-(2-ethoxy-phenyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4-trifluoromethoxy-benzyl)-oxazolidin-4-one; 3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-naphthalen-2-ylmethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-propoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4-trifluoromethoxy-benzyl)-(R)-5-methyl-oxazolidin-4-one; 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-naphthalen-2-ylmethyl-oxazolidin-4-one; 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-(S)-5-methyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; 3-Benzothiazol-2-ylmethyl-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-(R)-5-methyl-3-(4-trifluoromethoxy-benzyl)-oxazolidin-4-one; 3-Benzothiazol-2-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; 3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-(S)-5-methyl-3-naphthalen-2-ylmethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(3-fluoro-4-trifluoromethoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; 3-Benzooxazol-2-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; 3-(4-Difluoromethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(1-methyl-1H-benzoimidazol-2-ylmethyl)-oxazolidin-4-one; 3-Benzo[1,3]dioxol-5-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-methoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; (R)-2-(2,6-Dimethoxy-phenyl)-5-methyl-3-(4-propoxy-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)-(R)-5-methyl-oxazolidin-4-one; 3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-(R)-5-methyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-isopropoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-propoxy-benzyl)-oxazolidin-4-one; 3-(4-Cyclopropylmethoxy-benzyl)-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-ethoxy-benzyl)-(R)-5-methyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-3-(4-ethoxy-benzyl)-5,5-dimethyl-oxazolidin-4-one; 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-dimethyl-phenyl)-5,5-dimethyl-oxazolidin-4-one; 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2,6-difluoro-phenyl)-5,5-dimethyl-oxazolidin-4-one; 3-(3-Chloro-4-trifluoromethoxy-benzyl)-2-(2-methoxy-6-methyl-phenyl)-5,5-dimethyl-oxazolidin-4-one; 2-(2-Fluoro-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 2-(2-Chloro-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 2-(2-Methoxy-6-trifluoromethyl-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 3-Biphenyl-4-ylmethyl-2-(2,6-dimethoxy-phenyl)-5,5-dimethyl-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(4-trifluoromethylsulfanyl-benzyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(6-phenoxy-pyridin-3-ylmethyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-(5-phenoxy-pyridin-2-ylmethyl)-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(pyridin-2-yloxy)-benzyl]-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(pyrazin-2-yloxy)-benzyl]-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(6-methyl-pyridazin-3-yloxy)-benzyl]-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(thiazol-2-yloxy)-benzyl]-oxazolidin-4-one; 2-(2,6-Dimethoxy-phenyl)-5,5-dimethyl-3-[4-(pyrimidin-2-yloxy)-benzyl]-oxazolidin-4-one; 2-(2-Isopropoxy-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 2-(2-Ethoxy-6-methoxy-phenyl)-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; 2-[2-Methoxy-6-(2-methoxy-ethoxy)-phenyl]-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; and 2-[2-(3-Hydroxy-propoxy)-6-methoxy-phenyl]-5,5-dimethyl-3-(4-phenoxy-benzyl)-oxazolidin-4-one; in a free or a pharmaceutically acceptable salt.
 12. The pharmaceutical composition containing, as active principle, the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
 13. (canceled)
 14. A method for the treatment or prophylaxis of a disease or disorder wherein the compound of claim 1 is administered to a subject, wherein said disease or disorder is selected from the group consisting of: all types of sleep disorders, of stress related syndromes, of addictions, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, and eating or drinking disorders.
 15. (canceled) 